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Abstract
1. Both EACA and AMCHA clearly showed an anti-inflammatory effect, by intravenous,
intramuscular, or oral route, against inflammatory edema produced in rats by intracutaneous in-
jection of rabbit’s anti-rat serum, carrageenin, histamine, serotonin, or bradykinin, as tested by
the punch method. 2. The two compounds also showed inhibitory action against the cotton pellet
granuloma when used in a larger dose. 3. There was virtually no difference between the two
compounds in their anti-inflammatory activity, in spite of the fact that antiplasmin activity of AM-
CHA is evidently greater than that of EACA. In addition, there was no increase in fibrinolysis
at the site of antiserum inflammation in rats. Therefore, it would be difficult to presume that the
anti-inflammatory action of these compounds is due to their antiplasmin activity. 4. Salicylates,
pyrazolidine derivatives, and non-steroidal antiinflammatory agents like flufenamic acid inhibited
degranulation of isolated rat mast cells induced by compound 48/80 and also inhibited ATP-32Pi
exchange reaction in rat liver mitochondria, but such actions were not observed in EACA or AM-
CHA. 5. Anti-inflammatory effect of EACA and AMCHA did not decrease after adrenalectomy
but did become weak in hypophysectomized rats. EACA did not increase blood sugar level in
normal rats so that its antiinflammatory action is not due to hyperglycemia, and the effect of hy-
pophysectomy may not be correlated to carbohydrate metabolism. 6. Anti- inflammatory effect
of EACA and AMCHA appeared more rapidly after intramuscular or oral administration than by
intravenous injection but the effect was not fortified after their in vitro incubation with tissues of
stomach, intestine, or liver.
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It has been shown that salicylates, pyrazolone derivatives, and other
antipyretics inhibit certain experimental allergy and histamine release (I-
3). These compounds are also known to inhibit plasma protease, considered
to be plasmin, in vitro, in a concentration attainable in circulating blood
after administration of a therapeutic dose (4, 5). Since activation of pro-
teases, including plasmin, may occur during antigen-antibody reaction
and in inflammation (6), and since the activated p~asmin can form phlo-
gogenic kinins from kininogens (a2-globulin) in the plasma, either indirectly
or directly (7-15), it is possible to presume anti-allergic or anti-inflam-
matory action in substances that inhibit the activation or action of plasmin.
Fragmentary reports have already appeared on the anti-allergic effect
of an antiplasmin agent, e-aminocaproic acid (EACA). trans-(4-Amino-
methyl)-cyclohexanecarboxylic acid (AMCHA), newly introduced by
OKAMOTO and OKAMOTO (6) is said to possess far more potent antiplasmin
activity than EACA as determined by a fibrinolytic test 06-18). Reports
have also been made on the absorption, excretion, and blood level of
these two compounds (19-21).
The present report demonstrates that both EACA and AMCHA show
a fairly marked inhibitory effect on experimental inflammation in rats,
as tested by the punch method, and also gives result of a few experiments
carried out for attempted elucidation of the mechanism of such action.
MATERIALS AND METHODS
Anti-inflammatory assay. Evaluation was made by the punch method devised
by UNGAR et al. (22), in which anti-inflammatory effect of drugs is based on the
inhibition of the cutaneous edema provoked by antiserum. Male Wistar rats (150
±5 g) received intradermally a total of 8 injections in the previously shaved skin
* The main part of this study has been published in Japanese (Folia pharmac. japan., 63,
560, 1957).
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of the back, 4 sites on each side of the midline. One side received the lyophilized
anti-rat rabbit serum, 5 mg per site in 0.05 ml physiological saline, while the
opposite side was injected with saline of the same quantity, through a 27-gauge
needle. Two hours after injection of the antiserum, when the edema reached the
maximum, the rats were stunned and bled to death. The excised piece of skin,
with the fur-side down, was pinned on a wooden board and injected sites were
cut out with a steel punch (diam. 12 mm, area 112 mm2). Each piece of skin was
immediately weighed on a torsion balance. Intensity of inflammation is expressed
as Ir-=(W j -Ws)100/Ws, where WI is the weight of inflammatory site.and W s is
the weight of the saline-injected site. The Ie value taken from 16 animals, 64 test
and 64 control sites, gave a mean of 89±0.68 (8.E.). Anti-inflammatory activity
is expressed in terms of per cent inhibition of inflammation, i. e., (Ie- I() 100/Ie,
where Ie is the intensity of inflammation in the non-treated control animals and
It is the same in the animals treated with the drug under test. In each test for a
drug, It was usually expressed as the mean of 8-12 values obtained from 2-3
animals. Drugs were administered by either intravenous, intramuscular, or oral
route, and volume of the solution was I ml/150 g body weight. When observa-
tion was made on the time course of the activity, the intervals between administ-
ration of the drug and injection of phlogogenic substance were varied from 30
min to 24 hr. Intravenous injection was made into the tail vein, and intramus-
cular injection was divided into both sides of femoral muscle.
In some of the experiments, carrageenin, histamine, serotonin, bradykinin,
and formaldehyde solutions were also used as the phlogogenic substance. Table I
TABLE 1. STANDARD DOSES OF PHLOGOGENIC SUBSTANCES AND THEIR EFFECTS
Phlogogenic substance Dose Weight increase
Time of determination
of skin (%) after injection (hr)
Anti-rat serum 5 mg 89±0.68 (64)a 2
Histamine" 20 Ilg (base) 56±0.80 (16) I
Serotonin 20 Ilg (base) 53±0.67 (16) 2
Bradykinin 7.51lg 50±0.64 (24) 1
Carrageenin 0.5mg 52 ± 1. 32 (24) 3
Formaldehyde 5 mg 93±1.48 (12) 3
a) Number of test sites.
II) In guinea pigs, the others in rats.
gives the doses of phlogogenic substances injected, the time of determination of
inflammation after injection, and the intensity of inflammation, Ie, at the time
of determination, i. e., the per cent weight increase of skin. Guinea pigs (male,
230± 10 g) were also used but only for histamine inflammation and drugs to be
tested were given by cardiac puncture. Anti-rat serum was obt<:\.ined from rabbits
which had received 9 intravenous injections of I ml of rat serum every other day
and blood was drawn 10 days after the last injection, and the serum was lyophi-
lized.
Assay of inhibitory effect on granuloma. The cotton pellet method of ROBINSON
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and ROBSON (23) was slightly modified; details have already been reported (24).
Hypophysectomy and adrenalectomy. Rat hypophysis was extirpated by TANAKA'S
auditory canal method (25). Only the animals in healthy state one week after the
operation were used for the experiments. Bilateral adrenalectomy was performed
from both sides of the back under ether anesthesia, and the animals were used
for the experiment 3 days after the operation, during which period drinking
water contained 0.9% saline. Absence of accessory adrenals was confirmed after
the experiment.
Measurement of blood glucose. The glucose oxidase-peroxidase method of
HUGGETT and NIXON (26) was used. Blood was drawn from the carotid artery.
Test for inhibition of degranulation of rat mast cells. The method was the same as
that of YAMASAKI and SAEKI (27) using rat mast cells isolated from peritoneal
fluid. The effect was represented as the drug concentration to effect 50% inhibi-
tion of mast-cell degranulation produced by 0.5.ug/ml of compound 48/80 in a
buffered physiological solution.
A TP-32Pi exchange reaction. Mitochondria were isolated by centrifugation from
the liver of Wistar rats (male or female) weighing 150-200 g, by the method of
HOGEBOOM (28). For the preparation of homogenate, 0.25 M sucrose solution
containing 40.uM of EDTA-Na2 and 1 mM of Tris-HCl buffer (pH 7.4) was
used. The isolated mitochondria were suspended in 0.25 M sucrose solution
containing 1 mM of Tris-HCl buffer (pH 7.4). All these procedures were carried
out at 0-4°C. The protein contents were measured by the method of LOWRY et
al. (29).
The medium for ATP- 32Pi exchange reaction in mitochondria contained the
following in a final volume of 2.0 ml: 0.1 M sucrose, 20 mM KCl, 10 mM Tris-
HCl buffer (pH 7.4), 40.uM EDTA-Na2" 3 mM potassium phosphate buffer
(pH 7.4) containing 200,000 cpm of 32p, 3 mM ATP, and the drug under test,
which was omitted in the control experiment. After addition of mitochondria
corresponding to 2.9 mg of protein to this medium, the reaction was allowed to
proceed in test tubes at 25°C. Incorporation of 32p into organic matter was
measured by the method of HAGIHARA and LARDY (30). After incubation for 10
min, 0.5 ml of the reaction mixture was added to 1 ml of HAGIHARA'S Reagent
A in test tubes which were kept in an ice bath. To the mixtures, 1.5 ml of Rea-
gent B was added, and, after left standing for a few min, this mixture was applied
to a reverse-phase siliconized Celite column. In a planchet 1 ml of the effluent
was placed, dried, and radioactivity was counted by a GM counter.
Measurement offibrinolytic activity. Standard and heated (60-85°C, 30 min)
fibrin plates were used. In a dish of 4.5 cm diameter, 1 ml of fibrinogen solution
and 2 ml of buffer solution were placed, one drop of thrombin solution was
added while gently moving the dish, and the dish was allowed to stand until the
mixture formed a white jelly-like mixture. This was allowed to stand in an incu-
bator of 37°C for 30 min to dry the surface. Fibrinogen solution was prepared
from 100 ml of bovine plasma according to the method of ASTRUP and MULLERTZ
(31), fractionally precipitated with ammonium sulfate, washed with cold distilled
water, and dissolved in 40 ml of buffer solution (662 ml of 0.1 M barbital sodium,
3
Yamasaki et al.: Anti-inflammatory effect of antiplasmin agents,
Produced by The Berkeley Electronic Press, 1970
512 H. YAMASAKI, H. TSUJI and M. KITAMURA
338 ml of 0.1 M HC1, and 320 ml of distilled water). Bovine thrombin was dis-
solved to contain 100 units in 1 ml of physiological saline solution.
On the back skin of a rat 5 mg of rabbit's anti-rat serum was given by intra-
cutaneous injection to produce antiserum inflammation. The injected skin was
punched as described above after various time intervals (immediately after,
and 3, 5, 10, 30, 60, and 120 min) and the skin was placed gently on the fibrin
plate, with the subcutaneous tissue touching the plate. The dish was covered,
placed in an incubator (37°C), and dissolution of fibrin was tested at various
time intervals during the next 30 min to 24 hr. The control experiment was made
on the skin in jected with saline solution not containing antiserum.
Chemicals and reagents. EACA and AMCHA used were crystalline products
supplied by the Daiichi Pharmaceutical Co., Tokyo. Phlogogenic substances
used were carrageenin (Genu Carrageenan, Pectin Factory, Copenhagen),
dextran (Meiji Seito Co., avo mol. wt., 54, 000), histamine hydrochloride (Wako
Pure Chemical Co., Osaka), serotonin creatinine sulfate (Sigma Chemical Co.,
U. S. A.), bradykinin (Protein Research Institute, Osaka University), and form-
aldehyde (Formalin, ]. P.). Compound 48/80 was kindly donated by the Bur-
roughs Wellcome Laboratories, New York, and disodium salt of ATP was a
product of Sigma Chemical. Bovine thrombin was purchased from Mochida
Pharmaceutical Co. All other reagents used were the purest commercial grade.
RESULTS
A. Anti-inflammatory effect
1. Inhibition of antiserum edema. After intravenous injection of 100
mgJkg of EACA or AMCHA, the rats were divided into seven groups of
2-3 each and antiserum was injected intracutaneously on their back 0.5,
1, 2, 3, 5, 8, and 24 hr later. Edema intensity, i. e., weight increase of skin,
was compared with that of non-treated control, and percentage of inhibi.
tion of edema was calculated as mentioned before. The same experiments
were carried out with intramuscular and oral administration of these
drugs. The results are shown in Fig. 1.
In the case of intravenous injection, edema inhibition was the most
remarka ble when antiserum was injected 2 hr after the administration of
the drug, both EACA and AMCHA. In other words, effect of the drugs
bacomes maximum 2 hr after their administration. In the oral administ-
ration, the maximum inhibition appeared after 30 min while that appeared
I hr after intramuscular administration. It is of interest that the effect of
intravenous administration reached the maximum later than that of oral
or intramuscular administration. The effect decreased with longer interval
between administration of drug and antiserum injection but some effect
remained even 24 hr after the drug administration. There was no dif-
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Fig. 1. Time course of the anti-inflammatory effects of EACA and AMCHA
on antiserum-induced cutaneous edema in rats. Ordinate: % reduction in weight
increase of skin produced by antiserum 5 mg per site; abscissa: time intervals
at which antiserum was injected after administration of the drugs. Each point
represents the mean of 8-12 test and 8-12 control sites from 2-3 rats.
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Fig. 2. Anti-inflammatory effects of EACA and AMCHA on the cutaneous edema
produced by various phlogogenic substances. Ordinate: % reduction of weight increase;
abscissa: dose (log scale). Standard inflammations were produced by intradermal injec-
tion of phlogogenic substances in doses per site listed in Table 1. EACA and AMCHA
were injected intravenously 2 hr before the injection of phlo6ogenic substances. Hista-
mine inflammation was produced in guinea pig, the others in rat. Each point represents
the mean of 8-12 test and 8-12 control sites from 2-3 animals.
ference in such effect between EACA and AMCHA, and the degree of
the effect was hardly distinguishable between these two drugs. Intravenous
route gave slightly better effect than oral or intram'uscular route in either
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drug. In the dose used (l00 mgjkg), half-life of the effect lies between 5
and 8 hr by any route of administration.
Dose-effect relationship in the inhibitory effect of EACA and AMCHA,
administered by intravenous route 2 hr before antiserum, is shown by a
straight line based on log dose scale, as indicated on the far left in Fig. 2.
There is no difference between the two drugs in the effect, and their dose
for 50 % inhibition of edema is around 60 mg/kg.
Since some effect of both drugs was seen even after 24 hr, possible
cumulative effect was examined by intravenous injection of 100 mg/kg of
either drug during the forenoon every day for 1-5 days. Three animals
each were taken after each administration, and antiserum injection was
given 20 hr after the last administration of the drug. As shown in Fig. 3,
5
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Fig. 3. Anti-inflammatory effects of successive daily injection of EACA and
AMCHA. Ordinate: % reduction of weight increase; abscissa: days of determi-
nation of the effect. Arrows indicate an intramuscular injection of drugs (l00
ms!kg), 20 hr prior to every anti-inflammatory test. Each point represents the
mean of 8 test and 8 control sites from 2 rats.
increase in the effect, suggesting accumulation of the action, was seen
until second administration of EACA but the residual effect rather tended
to decrease 20 hr later after the third injection. This decrease in the effect
already appeared after second injection of AMCHA. These results indicate
that repeated injection of 100 mg/kg dose every 24 hr does not produce
accumulation of the effect.
2. Inhibition of edema produced by carrageenin, histamine, serotonin, brady-
kinin, and formaldehyde. Anti-inflammatory dose-effect curves were ob-
tained for intravenously injected EACA and AMCHA against inflamma-
tory edema produced by the title substances (guinea pigs for histamine,
rats for others). Experiments were carried out exactly as in the foregoing i:li
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case using antiserum edema, and the results are shown in Fig. 2. Both
drugs were ineffective on formaldehyde inflammation but showed in-
hibitoryeffect on inflammation by other sub.~tances. There was no dif-
ference between the two drugs in the intensity of their effect. The dose
for 5096 edema inhibition was 85-120 mgjkg for carrageenin, 100-115
mgjkg for histamine, 60 mgjkg for serotonin, and 110-120 mgjkg for
bradykinin inflammation.
3. Inhibition of granuloma. After implantation of cotton pellets, the
drug was given by intramuscular injection every day for six days and the
pellets were taken out 24 hr after the last injection. The result shown in
Table 2 indicates that 200 mgjkgjday of EACA gives a slight inhibition
TABLE 2. EFFECT OF EACA, AMCHA AND HYDROCORTISONE ACETATE
ON COTTON PELLET GRANULOMA IN RATS
Treatment Daily dose Pellet weight Granulation tissue Effect p(mg/kg) (mg) (mg±S. E.) (%)
Controls 8.2 13.3±0.53
EACA 100 8.2 13.0±0.49
Controls 7.2 12.1 ±0.51
EACA 200 7.2 1O.3±0.34 15.1 < 0.05
EACA 500 7.2 9.2±0.39 24.1 < 0.001
Controls 7.4 1O.8±0.35
AMCHA 100 7.4 1O.4±0.88
AMCHA 200 7.4 1O.1±0.36 5.5 < 0.1
AMCHA 500 7.4 8.5±0.27 21.3 < 0.001
Controls 10.5 17.2±0.48
Hydrocortisone 10 10.5 12.6±0.25 26.3 < 0.001
Controls 7.2 12.1 ±0.51
Hydrocortisone 40 7.2 7.4±0.24 38.8 < 0.001
4-6 animals per group.
but the reliable inhibitory effect required a large dose of 500 mgjkgjday
of both drugs. In this dose, the effect of these drugs was close to that of
10 mgjkgjday of hydrocortisone.
B. Anti-inflammatory effect in adrenalectomized and in hypophysectomized
rats
Oral and intravenous dose-effect curves of EACA and AMCHA on
anti-rat serum edema wer.:: examined w.i.th adr.::nalectomized and hypophy-
sectomized rats. Results are shown in Fig. 4 in comparison with that of
normal rats. Edema was stronger in the adrenalectomized than normal
rats, but weaker in hypophysectomized rats. Due to such a difference,
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Fig. 4. Anti-inflammatory effects of
EACA and AMCHA in adrenalecto-
mized and in hypophysectomized rats.
Ordinate: % reduction of weight in-
crease; abscissa: dose (log scale). See
also Table 3.
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edema intensity is shown as the observed values of per cent weight In.
crease of skin in Table 3.
TABLE 3. ANTI-INFLAMMATORY EFFECTS OF EACA AND AMCHA IN ADRENALECTOMIZED
AND IN HYPOHYSECTOMIZED RATS ON ANTISERUM-INDUCED CUTANEOUS EDEMA.
Figures denote percentage of weight increase of s',in with S. E., and number of test sites: in
parentheses. Dose of antiserum, 5 mg in 0.05 ml per site.
Control
Dose (m~/kg)
30 60 100 120
Normal rats 89±0. 74 (20) EACA i.v. 62±0.9 (8) 46±0.6 (8) 30± 1.0 (8) 28±1.0 (8)
p.o. 66±2.1 (4) 50±0.7 (4) 35± 1.8 (4)
AMCHA i.v. 70±1.8 (8) 44±1.2 (8) 31±.1.0(8) 26± 1.1 (8)
p.o. 74±0.8 (4) 55± 1.9 (4) 42±1.9 (4)
Adrenalecto- 107 ± 1.17 (16) EACA i. v. 56±1.1 (8) 47±0.9 (8) 42± 1.0 (8) 37± 1.0 (8)
mized ratsa
p.o. 83±2.1 (4) 73±2.0 (4) 64±1.1 (4)
AMCHA i. v. 56± 1.1 (8) 49± 1.6 (8) 44± 1.5 (8) 39±1.8 (8)
p.o. 86± 1.8 (4) 77±1.4 (4) 70±1.3 (4)
Hypophysecto- 77 ± I. 17 (12) EACA i.v. 74±1.4 (8) 70±0.9 (8) 67± 1.6 (8)
mized ratsb AMCHA i.v. 76±1.3 (8) 71 ±0.9 (8) 67±1.0 (8)
a) Experiment performed 3 days after the operation. Drinking water contained 0.9% NaCI.
b) Experiment performed 7 days after the operation.
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Slope of the dose-effect curves of two drugs differs in the adrenalecto-
mized and hypophysectomized rats. Considering the data in Fig. 4 and
Table 3, the effect of two drugs cannot be said to decrease by adre-
nalectomy although hypophysectomy clearly decreases their effect.
C. Effect on degranulation of isolated rat mast cells induced by compound
48/80
Degranulation of mast cells by compound 48/80 or antiserum is con-
sidered to be dependent on energy generating capacity of these cells since
this reaction is inhibited by uncouplers of oxidative phosphorylation or
respiratory inhibitors in a glucose-free medium (32, 33). The uncoupling
properties of salicylates, pyrazolone derivatives, and some non-steroidal
anti-inflammatory agents have been shown by ADAMS and COBB (34),
BRODY (35), and by WHITEHOUSE (36). Recently, YAMASAKI and SAEKI
(27) reported that these non-steroidal anti-inflammatory agents inhibit
degranulation of mast cells by compound 48/80 in a medium not contain-
ing glucose and that this activity roughly parallels their anti-inflammatory
effect against antiserum inflammation examined by the punch method.
Table 4 shows the effect of EACA and AMCHA on mast-cell degranula-
tion by compound 48/80 together with the effect of some non-steroidal
anti-inflammatory agents and some known uncouplers (2, 4-dinitrophenol,
TABLE 4. EFFECTS OF EACA, AMCHA, AND OTHER DRUGS ON MAST-CELL DEGRANU-
LATION BY COMPOUND 48/80 AND ON INFLAMMATORY EDEMA BY ANTISERUM
Drug Cone. of 50% inhibition
of M. C. degranulation
Anti-inflam~atoryeffect
Dose Reduction of weight increase
mM mg/kg %
EACA 25 100a 67 ± I. 2
AMCHA 65 100a 65± 1.0
Sodium salicylate 1.5 250 43±0.5
Acetylsalicylic acid 1. 1 250 33 ± 1.0
Phenylbutazone 0.03 30 48± 1.1
Oxyphenbutazone 0.006 30b 52±0.5
Flufenamic acid 0.018 30 40±2.0
Mefenamic acid 0.062 30 49±1.3
Indomethacin 0.05 30b 57 ± 1.3
2,4-Dinitrophenol 0.02 30c 38±1.1
Dicumarol 0.02 30c 32 ± 1. 1
Warfarin sodium 0.16 30c 38±0.5
Amytal sodium 0.5 30 30 ± I. 1
a) Injected i. v. 2 hr before, b) i. m. 3 hr before, and c) s. c. 30 min before injection
of antiserum; while all the others were injected i. m. 2 hr before.
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dicumarol, warfarin sodium), and also their inhibitory effect on antiserum
inflammation. While non-steroidal anti-inflammatory agents showed a
marked inhibitory action on degranulation like known uncouplers, EACA
and AMCHA did not show any apparent activity despite their similar
anti-inflammatory effect.
D. Effect on ATP-32Pi exchange reaction in mitochondria
As shown in Table 5, ATP-32Pi exchange reaction in rat liver mito.
chondria is clearly inhibited by 0.01-0.05 mM of phenylbutazone, oxy-
TABLE 5. EFFECT OF EACA AND AMCHA ON THE A Tp_32PI EXCHANGE
REACTION IN RAT LIVER MITOCHONDRIA
Concentration
(mM) c.p.m.
Inhibition
(%)
None
EACA
AMCHA
Oxyphenbutazone
(-13)
(-10)
3
5
100
67
91
33
68
94
Flufenamic acid
Phenylbutazone
2,383
1 2,660
5 2,619
1 2,313
5 2,269
0.01 0
0.05 650
0.1 235
0.01 1,597
0.05 658
2,4-Dinitrophenol 0.01 136
Mitochodria, 2.9 mg protein/2 ml, 10 min incubation at 25°C.
phenbutazone, and flufenamic acid, effect of the last named being more
marked than that of dinitrophenol. However, such an effect was not
observed in either EACA or AMCHA.
E. Anti-inflammatory effect and blood sugar
It is known that anaphylactoid edema in rats produced by dextran or
egg white is inhibited in alloxan-diabetes and increased in insulin-induced
hypoglycemia (37, 38). Similar phenomena have been observed in the
edema by antiserum or other phlogogenic substances, as tested by the
punch method (39). Fig. 5 shows the relationship between blood sugar in
rats after administration of alloxan, glucose, or insulin, and intensity of
anti-rat serum edema, with the results obtained after intravenous injection
of EACA. As will be clear from these data, EACA hardly gave any effect
on blood sugar in a dose that showed anti-inflammatory effect, indicating
that its anti-inflammatory mechanism is not related to hyperglycemia.
10
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Fig. 5. Glycemia after treatment with EACA, alloxan, glucose or insulin.
EACA 100 mg/kg (i. Y.), glucose 10 g/kg (i. y.) or insulin 20 i. u. /kg (s. c.) was
injected just before zero min, and alloxan monohydrate 30 mg/kg (i. y.) 48 hr
before. Accompanying table indicates intensities of inflammatory edema produced
by antiserum injected intracutaneously at the point between 0 and 15 min in
abscissa. Figures in parentheses denote number of test and control sites.
F. Fibrinolytic test for antiserum inflammation
In order to know whether the afore-mentioned anti.inflammatory
effect of EACA and AMCHA was due to their antiplasmin activity, it is
necessary to examine whether the mechanism of inflammatory edema
produced in the rat involves activation of plasmin or not. Rats were given
intracutaneous injection of 5 mg of antiserum and the skin at injected sites
was punched immediately and 3, 5, 10, 15, 30, 60, and 120 min later.
Punched pieces of the skin were embedded in standard and heated plates,
and examined periodically up to 24 hr. It was thereby found that there
was no fibrinolysis, the same as in the control skin pieces obtained from
the site injected with saline solution.
G. Anti.inflammatory effect of EACA and AMCHA incubated with tissues
As stated above, the anti.inflammatory effect of EACA and AMCHA
appears much earlier after oral or intramuscular administration than by
intravenous injection and is especially rapid after oral administration.
However, rise in blood level of these compounds has been reported to be
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slower after oral administration than after subcutaneous Injection in
rabbits (9) and in man (21). This fact suggests the possibility that the
drugs administered through the oral route might be transformed into
other effective substance(s) after passing through the digestive tissues.
Therefore, EACA was incubated with gastric, intestinal, and liver tissue
pieces from rats, in Tyrode solution at 37°C for 30 min and its anti.
inflammatory effect was examined by intravenous administration. How-
ever, the effect of EACA was not increased but rather decreased by the
treatment (Table 6).
TABLE 6. ANTI.INFLAMMATORY EFFECT ON ANTISERUM EDEMA OF EACA
INCUBATED WITH TISSUES
% Reduction of weight increase
Tissue Time of antiserum injection after drug administration
1 hr 2 hr
None
Stomach
Intestine
Liver
Livera
53 ± 1. 34 (8)b
24± 1.84 (8)
18±1. 73 (8)
15±1.87 (8)
18±2.53 (8)
67±1.18 (8)
34±2.05 (8)
26± 1.09 (8)
28± 1.22 (8)
28±4.18 (8)
15 m:5 of EACA was incubated with 1.1 g tissue slices in 10 ml of 0.9 % saline (pH
7.2, adjusted) or a)Tyrode solution (pH 8.0) for 30 min at 37°C. Filtrate was injec-
ted i. v. in a dose corresponding to 100 mg per kg. b) Number of test sites.
DISCUSSION
There are many classical literatures suggesting the role of proteolytic
enzymes in allergic responses (40-43), and it is now well known that
activation of tissue proteolytic enzymes occurs at the site of allergic or
inflammatory reaction (6). These enzymes probably initiate a complex
chain reaction, which involves the formation of chemical mediators, lead-
ing to increased vascular permeability and to other events of inflammatory
processes. Such a protease activated at the site of allergy and inflamma.
tion is not a unity and can be discriminated by its substrate specificity
and pattern of inhibitors. Plasmin (fibrinolysin), one of such proteolytic
enzymes, is formed from plasminogen, a precursor present in plasma
euglobulin fraction, by its activation through the action of plasminogen
activators (fibrinokinase) which are formed in many tissues or in plasma.
Because of the difficulty of isolating plasmin in enzymically pure state, its
properties have not been clarified strictly and it is still not clear whether
it is a single enzyme or not (44, 45). However, its relation to inflamma-
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tion is being increasingly regarded important because of the recent
observations that plasmin takes part in the kinin forming system, either
acting directly on plasmakininogen or indirectly as an activator of pre·
enzyme (7-15).
It is known that salicylates and some kinds of anti.inflammatory
agent inhibit various enzymes (38, 46-48). UNGAR, DAMGAARD and
HUMMEL (4) reported that the inhibitory effect of some anti.inflammatory
agents including salicylates and pyrazolone derivatives on Arthus-type
arthritis of guinea pigs paralleled their in vitro plasmin inhibitory effect.
The present series of experiments also indicate that the antiplasmin
agents, EACA and AMCHA, evidently inhibit the reverse Arthus-type
inflammatory reaction of the rat skin. These two compounds also inhibited
inflammatory edema produced by carrageenin, histamine, serotonin, and
bradykinin, although they were ineffective against formaldehyde inflam-
mation. Such an effect was considerably marked in a dose level of 50
mg/kg, which is a little larger than the usual clinical dose of 500 mg/day
for 3-4 days. Inhibitory effect on cotton pellet granuloma was also
observed with a larger dose (over 200 mg/kg/day) for six days. However,
it would be difficult to consider that such an effect of these compounds is
due to their antiplasmin properties, whether it be the inhibition of plasmi-
nogen activation or of fibrinokinase activation. The main reason for this
is, first that there was no clear difference between these two compounds
in their anti.inflammatory effect in rats, in spite of the fact that inhibitory
effect of AMCHA against plasmin, tested with fibrinolytic or caseinolytic
activity, i~ far stronger than that of EACA, either in vitro (16-18) or in
vivo 06, 20), and second that there was no evidence of increased fibrino.·
lysis in the skin tissue at the site of antiserum inflammation of the rat.
The anti-inflammatory action of these two compounds may, therefore, be
accredited to a pharmacological action other than antiplasmin activity.
Mast-cell degranulation by compound 48/80 depends on the ATP.
forming capacity of these cells (32, 33) and is inhibited by salicylates,
pyrazolidine derivatives and a series of non-steroidal anti-inflammatory
agents (27), which are uncouplers of oxidative phosphorylation (34 - 36).
Neither EACA nor AMCHA inhibited this degranulation, and the two
compounds did not inhibit the ATP-32Pi exchange reaction in mitochondria,
differing from salicylates, pyrazolidine derivatives and flufenamic acid.
If the mechanism of the anti-inflammatory effect of many of non-steroidal
anti-phlogistics involves the interference of energy metabolism, which
may be required for the synthesis of ground substance in connective tissue
and for reactivity of vascular endothelium (27, 36), the mechanism of
13
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anti.inflammatory action of EACA and AMCHA must be regarded as
different in quality from the action of these other compounds.
Since the anti-inflammatory effect of EACA and AMCHA did not
markedly decrease after the removal of adrenals, their action may not be
due to stimulation of the pltuitary-adrenal axis. However, after hypo-
physectomy a decrease in the action was observed. This suggests the
presence of some relation of the action to hypophyseal secretion other
than the above system. The growth hormone of the hypophysis raises
blood sugar, decreases glucose resistance in normal animals, and antago-
nizes the action of insulin (49-51). On the other hand, anaphylactoid
inflammation induced by dextran or ovomucoid is inhibited in alloxan
diabetic rat while such a reaction is potentiated in insulin hypoglycemia
(37, 38). MASADA (39) recently reported that anti-rat serum inflammation
produced by the same method as in the present experiments also under.
went similar changes as in anaphylactoid inflammation. The decreased
inhibitory effect of EACA and AMCHA on antiserum inflammation in
hypophysectomized rat suggested that both drugs might have promoted
the secretion of growth hormone and raised the blood sugar level, but
these two compounds injected intravenously in normal animals failed
to show any effect on their blood sugar level; therefore, the presumed
mechanism of action must be denied.
A remaining possibility is to attribute the action of these compounds
to their metabolites into which they might be transformed. The fact that
the anti-inflammatory action of EACA and AMCHA appeared more
rapidly after intramuscular or oral administration than by intravenous
injection does not agree with the changes in blood level of these com-
pounds (20, 21), and leaves a doubt on the formation of an effective inter-
mediate in the digestive tract or other tissues. It would not be easy to
elucidate the actual state of this problem but, at least, increase in the
effect of these two compounds could not be proved by incubating them
with pieces of gastric, intestinal, or liver tissue.
As described above, EACA and AMACH showed a relatively marked
anti-inflammatory action against antiserum allergic inflammation and
anaphylactoid inflammation by other phlogogenic substances in rats. The
compounds also showed inhibitory effect against granuloma formation.
These effects may not be due to the so-called antiplasmin action, and
seem to be considerably different in the mechanism from the action of
the known non-steroidal anti-inflammatory agents. Further studies are
desirable to clarify this problem, and it would also be necessary to
examine carefully whether such anti.inflammatory effect observed in rats
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SUMMARY
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1. Both EACA and AMCHA clearly showed an anti-inflammatory
effect, by intravenous, intramuscular, or oral route, against inflammatory
edema produced in rats by intracutaneous injection of rabbit's anti-rat
serum, carrageenin, histamine, serotonin, or bradykinin, as tested by the
punch method.
2. The two compounds also showed inhibitory action against the
cotton pellet granuloma when used in a larger dose.
3. There was virtually no difference between the two compounds in
their anti-inflammatory activity, in spite of the fact that antiplasmin
activity of AMCHA is evidently greater than that of EACA. In addition,
there was no increase in fibrinolysis at the site of antiserum inflammation
in rats. Therefore, it would be difficult to presume that the anti-inflam-
matory action of these compounds is due to their antiplasmin activity.
4. Salicylates, pyrazolidine derivatives, and non-steroidal anti-
inflammatory agents like flufenamic acid inhibited degranulation of
isolated rat mast cells induced by compound 48/80 and also inhibited
ATP_32Pi exchange reaction in rat liver mitochondria, but such actions
were not observed in EACA or AMCHA.
5. Anti-inflammatory effect of EACA and AMCHA did not decrease
after adrenalectomy but did become weak in hypophysectomized rats.
EACA did not increase blood sugar level in normal rats so that its anti-
inflammatory action is not due to hyperglycemia, and the effect of hypo.
physectomy may not be correlated to carb::>hydrate metabolism.
6. Anti-inflammatory effect of EACA and AMCHA appeared more
rapidly after intramuscular or oral administration than by intravenous
injection but the effect was not fortified after their in vitro incubation with
tissues of stomach, intestine, or liver.
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